<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04072640</url>
  </required_header>
  <id_info>
    <org_study_id>2018-014-1</org_study_id>
    <nct_id>NCT04072640</nct_id>
  </id_info>
  <brief_title>Three Induction Treatments on Cryptococcal Meningitis</brief_title>
  <acronym>TITOC</acronym>
  <official_title>The Effect and Safety of Three Initial Introduction Treatments on HIV-infected Patients With Cryptococcal Meningitis: A Multi-center, Random and Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wenzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three induction treatment strategies [ voriconazole +5FC vs. amphotericin deoxycholate&#xD;
      (0.4-0.5 mg/kg/d)+5FC vs. amphotericin deoxycholate (0.7-1.0 mg/kg/d)+5FC ] for HIV-infected&#xD;
      patients with cryptococcal meningitis were compared.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-associated cryptococcal meningitis were randomly allocated into three induction treatment&#xD;
      as follow: 1) 14 days of voriconazole 200mg bid +5FC, 2) 28 days of amphotericin deoxycholate&#xD;
      (0.4-0.5 mg/kg/d) +5FC ; 3）14 days of deoxycholate (0.7-1 mg/kg/d) +5FC). After induction&#xD;
      treatment were finished, all groups switched into fluconazole(400mg/d) for two-month&#xD;
      consolidation treatment. 14-day early fungicidal rate, 90-day mortality, side effects , and&#xD;
      tolerances were compared between three groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>90-day Cryptococcal Meningitis (CM) related mortality</measure>
    <time_frame>90 days</time_frame>
    <description>analysis of 90-day CM-related mortality of patients in three induction treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early fungicidal rate in Cerebrospinal fluid (CSF)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Comparison of 2-week CSF early fungicidal activity in three induction treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine elevation</measure>
    <time_frame>0-90 days</time_frame>
    <description>TO observe the numbers of patients whose creatinine &gt; 110 mmol/L during antifungal therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypokalemia</measure>
    <time_frame>0-90 days</time_frame>
    <description>To observe the rate of hypokalemia in three groups during antifungal therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anemia</measure>
    <time_frame>0-90 days</time_frame>
    <description>Comparison of the numbers of patients with hemoglobin &lt;120g/L for male or &lt;110g/L for female.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cryptococcal Meningitis</condition>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>voriconazole treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>induction treatment with Voriconazole 200mg bid (IV) + 5FC (100mg/kg/d) for 14 days, consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amphotericin treatment (0.7-1.0mg/kg/d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction treatment with amphotericin B 0.7-1.0mg/kg/d + 5FC (100mg/kg/d) for 14 days,consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amphotericin B treatment (0.4-0.5mg/kg/d)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction treatment with amphotericin B 0.4-0.5mg/kg/d + 5FC (100mg/kg/d) for 28 days, consolidation treatment with fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole 200mg</intervention_name>
    <description>Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;</description>
    <arm_group_label>voriconazole treatment</arm_group_label>
    <other_name>Voriconazole for Cryptococcus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amphotericin B deoxycholate (0.4-0.5mg/kg/d)</intervention_name>
    <description>Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days</description>
    <arm_group_label>amphotericin B treatment (0.4-0.5mg/kg/d)</arm_group_label>
    <other_name>low dose and long course of Amphotericin B-deoxycholate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)</intervention_name>
    <description>Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days</description>
    <arm_group_label>amphotericin treatment (0.7-1.0mg/kg/d)</arm_group_label>
    <other_name>standard Amphotericin B-deoxycholate for Cryptococcus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of HIV infection;&#xD;
&#xD;
          2. newly diagnosed Cryptococcal Meningitis by positive India ink staining or culture&#xD;
             result, or both in cerebrospinal fluid (CSF);&#xD;
&#xD;
          3. Anti-viral treatment naïve patients&#xD;
&#xD;
          4. anti-fungal treatment naïve patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. hepatitis virus co-infection;&#xD;
&#xD;
          2. liver cirrhosis;&#xD;
&#xD;
          3. congestive heart failure;&#xD;
&#xD;
          4. chronic renal disorders;&#xD;
&#xD;
          5. chronic obstructive pulmonary disease (COPD);&#xD;
&#xD;
          6. Tuberculosis co-infection;&#xD;
&#xD;
          7. malignances&#xD;
&#xD;
          8. severe mental and neurological diseases&#xD;
&#xD;
          9. Women during pregnancy and lactation&#xD;
&#xD;
         10. intraveneous drug user (IDU)&#xD;
&#xD;
         11. patients with follow abnormal test results:hemoglobin &lt; 6 g/dl, white blood cell count&#xD;
             &lt; 2000 / μl, neutrophil count &lt; 1000 / μl, platelet count &lt; 75000 / μl, blood amylase&#xD;
             &gt; 3 times normal level Upper limit, serum creatinine &gt; 1.5 times normal upper limit,&#xD;
             aspartate aminotransferase / alanine aminotransferase / alkaline phosphatase &gt; 3 times&#xD;
             normal upper limit, total bilirubin &gt; 2 times normal upper limit&#xD;
&#xD;
         12. patients who are unwilling to anticipate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lijun Xu, PH.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lijun Xu</name>
      <address>
        <city>Zhenjiang</city>
        <state>Hangzhou</state>
        <zip>310020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Voriconazole;amphotericin ;cryptococcal meningitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Amphotericin B, deoxycholate drug combination</mesh_term>
    <mesh_term>Deoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>12 months after study finished</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>12 months</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s).</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

